{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:21:50Z","timestamp":1781317310888,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA111882"],"award-info":[{"award-number":["CA111882"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Harris Family Foundation"},{"DOI":"10.13039\/100002300","name":"Rivkin Center for Ovarian Cancer","doi-asserted-by":"publisher","award":["584608"],"award-info":[{"award-number":["584608"]}],"id":[{"id":"10.13039\/100002300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging evidence has indicated that high-grade serous ovarian cancer (HGSOC) originates in the fallopian tube, where the earliest known genetic lesion is the mutation of <jats:italic>TP53<\/jats:italic>. In addition to such genetic changes, HGSOC is characterized by altered metabolism, including the production of oncogenic lipids such as lysophosphatidic acid (LPA). To understand the crosstalk between <jats:italic>TP53<\/jats:italic> mutations and LPA signaling, we utilized primary fallopian tube epithelial cells (FTEC) engineered to overexpress mutant p53. We found that gain-of-function (GOF) p53 mutations downregulated the LPA-degrading enzyme lysophosphatidic acid phosphatase type 6 (ACP6), leading to upregulation of focal adhesion signaling in an LPA-dependent manner. Although highly expressed in normal fallopian tube epithelium, ACP6 expression was significantly reduced in ovarian cancer tumors and early <jats:italic>in situ<\/jats:italic> lesions. Downregulation of ACP6 in ovarian cancer cells was necessary and sufficient to support HGSOC proliferation, adhesion, migration, and invasion. Using mouse models of metastasis, we established that attenuation of ACP6 expression was associated with increased tumor burden. Conversely, overexpression of ACP6 suppressed invasive behavior. These data identify an involvement of oncogenic p53 mutations in LPA signaling and HGSOC progression through regulation of ACP6 expression.<\/jats:p>","DOI":"10.1038\/s41598-019-41352-5","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T11:03:26Z","timestamp":1553598206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6"],"prefix":"10.1038","volume":"9","author":[{"given":"Agnieszka","family":"Chryplewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Tienda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik A.","family":"Nahotko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8624-1507","authenticated-orcid":false,"given":"Ernst","family":"Lengyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-3440","authenticated-orcid":false,"given":"Mark A.","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"41352_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","volume":"6","author":"MA Eckert","year":"2016","unstructured":"Eckert, M. A. et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov. 6, 1342\u20131351, https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0607 (2016).","journal-title":"Cancer Discov."},{"key":"41352_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127\u20131133, https:\/\/doi.org\/10.1038\/ng.2762 (2013).","journal-title":"Nat. Genet."},{"key":"41352_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmet","year":"2010","unstructured":"Ahmet, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49\u201356 (2010).","journal-title":"J. Pathol."},{"key":"41352_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"N The Cancer Genome Atlas","year":"2011","unstructured":"The Cancer Genome Atlas, N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"41352_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064, https:\/\/doi.org\/10.2353\/ajpath.2010.100105 (2010).","journal-title":"Am. J. Pathol."},{"key":"41352_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek, J. M. et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 195, 451\u2013456, https:\/\/doi.org\/10.1002\/path.1000 (2001).","journal-title":"J Pathol."},{"key":"41352_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn, E. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 226, 421\u2013426 (2012).","journal-title":"J. Pathol."},{"key":"41352_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/PGP.0b013e318216d447","volume":"30","author":"K Leonhardt","year":"2011","unstructured":"Leonhardt, K., Einenkel, J., Sohr, S., Engeland, K. & Horn, L. C. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int. J. Gynecol. Pathol. 30, 417\u2013424, https:\/\/doi.org\/10.1097\/PGP.0b013e318216d447 (2011).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"41352_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 211, 26\u201335, https:\/\/doi.org\/10.1002\/path.2091 (2007).","journal-title":"J Pathol."},{"key":"41352_CR10","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1038\/sj.onc.1202576","volume":"17","author":"SA Amundson","year":"1998","unstructured":"Amundson, S. A., Myers, T. G. & Fornace, A. J. Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17, 3287\u20133299, https:\/\/doi.org\/10.1038\/sj.onc.1202576 (1998).","journal-title":"Oncogene"},{"key":"41352_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268\u20131286, https:\/\/doi.org\/10.1101\/gad.190678.112 (2012).","journal-title":"Genes Dev."},{"key":"41352_CR12","doi-asserted-by":"publisher","first-page":"36031","DOI":"10.1074\/jbc.274.51.36031","volume":"274","author":"M Oren","year":"1999","unstructured":"Oren, M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274, 36031\u201336034 (1999).","journal-title":"J. Biol. Chem."},{"key":"41352_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2\u20138, https:\/\/doi.org\/10.1038\/ncb2641 (2013).","journal-title":"Nat. Cell Biol."},{"key":"41352_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.8023157","volume":"265","author":"Y Cho","year":"1994","unstructured":"Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346\u2013355 (1994).","journal-title":"Science"},{"key":"41352_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cmet.2016.10.011","volume":"24","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 24, 685\u2013700, https:\/\/doi.org\/10.1016\/j.cmet.2016.10.011 (2016).","journal-title":"Cell Metab."},{"key":"41352_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.trecan.2018.03.004","volume":"4","author":"E Lengyel","year":"2018","unstructured":"Lengyel, E., Makowski, L., DiGiovanni, J. & Kolonin, M. G. Cancer as a matter of fat: The crosstalk between adipose tissue and tumors. Trends Cancer 4, 374\u2013384, https:\/\/doi.org\/10.1016\/j.trecan.2018.03.004 (2018).","journal-title":"Trends Cancer"},{"key":"41352_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.280.8.719","volume":"280","author":"Y Xu","year":"1998","unstructured":"Xu, Y. et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719\u2013723 (1998).","journal-title":"JAMA"},{"key":"41352_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13277-010-0123-8","volume":"32","author":"I Sedlakova","year":"2011","unstructured":"Sedlakova, I., Vavrova, J., Tosner, J. & Hanousek, L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 32, 311\u2013316, https:\/\/doi.org\/10.1007\/s13277-010-0123-8 (2011).","journal-title":"Tumour Biol."},{"key":"41352_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1194\/jlr.R046458","volume":"55","author":"YC Yung","year":"2014","unstructured":"Yung, Y. C., Stoddard, N. C. & Chun, J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. 55, 1192\u20131214, https:\/\/doi.org\/10.1194\/jlr.R046458 (2014).","journal-title":"J. Lipid Res."},{"key":"41352_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc1143","volume":"3","author":"GB Mills","year":"2003","unstructured":"Mills, G. B. & Moolenaar, W. H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582\u2013591, https:\/\/doi.org\/10.1038\/nrc1143 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"41352_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/A:1008217129273","volume":"9","author":"AM Westermann","year":"1998","unstructured":"Westermann, A. M. et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 9, 437\u2013442 (1998).","journal-title":"Ann. Oncol."},{"issue":"Pt 2","key":"41352_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1042\/bj3360483","volume":"336","author":"M Hiroyama","year":"1998","unstructured":"Hiroyama, M. & Takenawa, T. Purification and characterization of a lysophosphatidic acid-specific phosphatase. Biochem. J. 336(Pt 2), 483\u2013489 (1998).","journal-title":"Biochem. J."},{"key":"41352_CR23","doi-asserted-by":"publisher","first-page":"29172","DOI":"10.1074\/jbc.274.41.29172","volume":"274","author":"M Hiroyama","year":"1999","unstructured":"Hiroyama, M. & Takenawa, T. Isolation of a cDNA encoding human lysophosphatidic acid phosphatase that is involved in the regulation of mitochondrial lipid biosynthesis. J. Biol. Chem. 274, 29172\u201329180 (1999).","journal-title":"J. Biol. Chem."},{"key":"41352_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s13238-013-3031-z","volume":"4","author":"J Li","year":"2013","unstructured":"Li, J. et al. Crystal structures and biochemical studies of human lysophosphatidic acid phosphatase type 6. Protein Cell 4, 548\u2013561, https:\/\/doi.org\/10.1007\/s13238-013-3031-z (2013).","journal-title":"Protein Cell"},{"key":"41352_CR25","first-page":"1551","volume":"15","author":"T Ando","year":"2006","unstructured":"Ando, T. et al. Expression of ACP6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol. Rep. 15, 1551\u20131555 (2006).","journal-title":"Oncol. Rep."},{"key":"41352_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models. Cancer Cell 24, 751\u2013765 (2013).","journal-title":"Cancer Cell"},{"key":"41352_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0092-8674(92)90163-7","volume":"70","author":"AJ Ridley","year":"1992","unstructured":"Ridley, A. J. & Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389\u2013399 (1992).","journal-title":"Cell"},{"key":"41352_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1006\/gyno.2002.6831","volume":"87","author":"K Sawada","year":"2002","unstructured":"Sawada, K. et al. Lysophosphatidic acid induces focal adhesion assembly through Rho\/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol. Oncol. 87, 252\u2013259 (2002).","journal-title":"Gynecol. Oncol."},{"key":"41352_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep06024","volume":"4","author":"YL Hu","year":"2014","unstructured":"Hu, Y. L. et al. FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells. Sci. Rep. 4, 6024, https:\/\/doi.org\/10.1038\/srep06024 (2014).","journal-title":"Sci. Rep."},{"key":"41352_CR30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1124\/mol.64.4.994","volume":"64","author":"H Ohta","year":"2003","unstructured":"Ohta, H. et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64, 994\u20131005, https:\/\/doi.org\/10.1124\/mol.64.4.994 (2003).","journal-title":"Mol. Pharmacol."},{"key":"41352_CR31","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Ladanyi","year":"2018","unstructured":"Ladanyi, A. et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37, 2285\u20132301, https:\/\/doi.org\/10.1038\/s41388-017-0093-z (2018).","journal-title":"Oncogene"},{"key":"41352_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12645","volume":"7","author":"F Coscia","year":"2016","unstructured":"Coscia, F. et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7, 12645, https:\/\/doi.org\/10.1038\/ncomms12645 (2016).","journal-title":"Nat. Commun."},{"key":"41352_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/ERC-11-0329","volume":"19","author":"B Gyorffy","year":"2012","unstructured":"Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 19, 197\u2013208, https:\/\/doi.org\/10.1530\/ERC-11-0329 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"41352_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","volume":"6","author":"D Rhodes","year":"2004","unstructured":"Rhodes, D. et al. Oncomine: A cancer microarray database and integrated data-mining platform. Neoplasia 6, 1\u20136 (2004).","journal-title":"Neoplasia"},{"key":"41352_CR35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber, E. R. & Lowe, S. W. Putting p53 in Context. Cell 170, 1062\u20131078, https:\/\/doi.org\/10.1016\/j.cell.2017.08.028 (2017).","journal-title":"Cell"},{"key":"41352_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbalip.2012.08.015","volume":"1831","author":"DN Brindley","year":"2013","unstructured":"Brindley, D. N., Lin, F. T. & Tigyi, G. J. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta 1831, 74\u201385, https:\/\/doi.org\/10.1016\/j.bbalip.2012.08.015 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"41352_CR37","first-page":"3534","volume":"9","author":"JL Tanyi","year":"2003","unstructured":"Tanyi, J. L. et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin. Cancer Res. 9, 3534\u20133545 (2003).","journal-title":"Clin. Cancer Res."},{"key":"41352_CR38","first-page":"1073","volume":"63","author":"JL Tanyi","year":"2003","unstructured":"Tanyi, J. L. et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res. 63, 1073\u20131082 (2003).","journal-title":"Cancer Res."},{"key":"41352_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1083\/jcb.200204026","volume":"158","author":"M Umezu-Goto","year":"2002","unstructured":"Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227\u2013233, https:\/\/doi.org\/10.1083\/jcb.200204026 (2002).","journal-title":"J. Cell Biol."},{"key":"41352_CR40","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4161\/cc.8.22.9937","volume":"8","author":"S Liu","year":"2009","unstructured":"Liu, S., Murph, M., Panupinthu, N. & Mills, G. B. ATX-LPA receptor axis in inflammation and cancer. Cell cycle 8, 3695\u20133701, https:\/\/doi.org\/10.4161\/cc.8.22.9937 (2009).","journal-title":"Cell cycle"},{"key":"41352_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ccr.2009.03.027","volume":"15","author":"S Liu","year":"2009","unstructured":"Liu, S. et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorignesis, invasion and metastases. Cancer Cell 15, 539\u2013550 (2009).","journal-title":"Cancer Cell"},{"key":"41352_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"MP Kim","year":"2018","unstructured":"Kim, M. P. & Lozano, G. Mutant p53 partners in crime. Cell Death Differ. 25, 161\u2013168, https:\/\/doi.org\/10.1038\/cdd.2017.185 (2018).","journal-title":"Cell Death Differ."},{"key":"41352_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drup.2018.05.001","volume":"38","author":"T Stiewe","year":"2018","unstructured":"Stiewe, T. & Haran, T. E. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat 38, 27\u201343, https:\/\/doi.org\/10.1016\/j.drup.2018.05.001 (2018).","journal-title":"Drug Resist Updat"},{"key":"41352_CR44","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0002-9440(10)63370-6","volume":"165","author":"AK Sood","year":"2004","unstructured":"Sood, A. K. et al. Biological significance of focal adhesion kinase in ovarian cancer. Am. J. Pathol. 165, 1087\u20131095 (2004).","journal-title":"Am. J. Pathol."},{"key":"41352_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep09529","volume":"5","author":"DJ McGrail","year":"2015","unstructured":"McGrail, D. J. et al. Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner. Sci. Rep. 5, 9529, https:\/\/doi.org\/10.1038\/srep09529 (2015).","journal-title":"Sci. Rep."},{"key":"41352_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep12642","volume":"5","author":"JG Lee","year":"2015","unstructured":"Lee, J. G., Ahn, J. H., Jin Kim, T., Ho Lee, J. & Choi, J. H. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals. Sci. Rep. 5, 12642, https:\/\/doi.org\/10.1038\/srep12642 (2015).","journal-title":"Sci. Rep."},{"key":"41352_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08880-4","volume":"7","author":"JH Ahn","year":"2017","unstructured":"Ahn, J. H., Kim, T. J., Lee, J. H. & Choi, J. H. Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells. Sci. Rep. 7, 9076, https:\/\/doi.org\/10.1038\/s41598-017-08880-4 (2017).","journal-title":"Sci. Rep."},{"key":"41352_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1172\/JCI67280","volume":"124","author":"A Arjonen","year":"2014","unstructured":"Arjonen, A. et al. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J. Clin. Invest. 124, 1069\u20131082, https:\/\/doi.org\/10.1172\/JCI67280 (2014).","journal-title":"J. Clin. Invest."},{"key":"41352_CR49","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1038\/onc.2017.66","volume":"36","author":"R Shakya","year":"2017","unstructured":"Shakya, R. et al. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. Oncogene 36, 4469\u20134480, https:\/\/doi.org\/10.1038\/onc.2017.66 (2017).","journal-title":"Oncogene"},{"key":"41352_CR50","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/nprot.2012.097","volume":"7","author":"AM Karst","year":"2012","unstructured":"Karst, A. M. & Drapkin, R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 7, 1755\u20131764, https:\/\/doi.org\/10.1038\/nprot.2012.097 (2012).","journal-title":"Nat. Protoc."},{"key":"41352_CR51","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1096\/fj.12-220160","volume":"27","author":"DH Kim","year":"2013","unstructured":"Kim, D. H. & Wirtz, D. Focal adhesion size uniquely predicts cell migration. FASEB J. 27, 1351\u20131361, https:\/\/doi.org\/10.1096\/fj.12-220160 (2013).","journal-title":"FASEB J."},{"key":"41352_CR52","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).","journal-title":"Nucleic Acids Res."},{"key":"41352_CR53","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny, H. A. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614\u20134628, https:\/\/doi.org\/10.1172\/JCI74778 (2014).","journal-title":"J. Clin. Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41352-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:08:18Z","timestamp":1671264498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41352-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41352-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5195"}}